-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Golimumab in Castration-Resistant Prostate Cancer (CRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Golimumab in Castration-Resistant Prostate Cancer (CRPC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Golimumab in Castration-Resistant Prostate Cancer (CRPC) Drug Details: Golimumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Golimumab in Type 1 Diabetes (Juvenile Diabetes)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Golimumab in Type 1 Diabetes (Juvenile Diabetes) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Golimumab in Type 1 Diabetes (Juvenile Diabetes) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Upadacitinib ER in Alopecia Areata
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Upadacitinib ER in Alopecia Areata report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Upadacitinib ER in Alopecia Areata Drug Details: Upadacitinib (Rinvoq, Rim-Voq)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Upadacitinib ER in Vitiligo
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Upadacitinib ER in Vitiligo report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Upadacitinib ER in Vitiligo Drug Details: Upadacitinib (Rinvoq, Rim-Voq) is an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Upadacitinib ER in Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Upadacitinib ER in Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Upadacitinib ER in Systemic-Onset Juvenile Idiopathic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Upadacitinib ER in Hidradenitis Suppurativa
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Upadacitinib ER in Hidradenitis Suppurativa report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Upadacitinib ER in Hidradenitis Suppurativa Drug Details: Upadacitinib (Rinvoq, Rim-Voq)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Upadacitinib ER in Oligoarticular Idiopathic Juvenile Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Upadacitinib ER in Oligoarticular Idiopathic Juvenile Arthritis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Upadacitinib ER in Oligoarticular Idiopathic Juvenile Arthritis Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Upadacitinib ER in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Upadacitinib ER in Systemic Lupus Erythematosus report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Upadacitinib ER in Systemic Lupus Erythematosus Drug Details: Upadacitinib...
-
Product Insights
Likelihood of Approval Analysis for Polymyalgia Rheumatica (PMR)
Overview How likely is it that the drugs in Polymyalgia Rheumatica (PMR) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Polymyalgia Rheumatica (PMR) Overview Polymyalgia rheumatica (PMR) is a rheumatic disorder...
-
Product Insights
Shandong Juxian CRP Wind Farm
Shandong Juxian CRP Wind Farm is an Onshore Wind project located in Shandong, China. The project is owned and developed by China Resources Power Holdings Co Ltd. The project came online in 2012. Empower your strategies with our Shandong Juxian CRP Wind Farm report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays....